BIO-key PortalGuard vs RSA ID Plus: Side-by-Side Comparison (2026)

BIO-key PortalGuard: Zero Trust IAM platform with MFA, SSO, passwordless auth, and SSPR. built by BIO-key International. Core capabilities include Multi-Factor Authentication (MFA) with 16 supported authentication methods, Passwordless authentication via biometrics (palm, face) and passkeys, Single Sign-On (SSO) including thick client application support..

RSA ID Plus: IAM platform with MFA, SSO, and adaptive access for cloud, hybrid, on-prem. built by RSA Security LLC. Core capabilities include Multi-factor authentication with FIDO, biometrics, OTP, mobile push, SMS/voice, Single sign-on with SAML 2.0 and OIDC federation, Adaptive access controls with contextual rules..

Both serve the MFA & Passwordless market but differ in approach, feature depth, and target audience.

BIO-key PortalGuard differentiates with Multi-Factor Authentication (MFA) with 16 supported authentication methods, Passwordless authentication via biometrics (palm, face) and passkeys, Single Sign-On (SSO) including thick client application support. RSA ID Plus differentiates with Multi-factor authentication with FIDO, biometrics, OTP, mobile push, SMS/voice, Single sign-on with SAML 2.0 and OIDC federation, Adaptive access controls with contextual rules.

BIO-key PortalGuard is developed by BIO-key International. RSA ID Plus is developed by RSA Security LLC. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

BIO-key PortalGuard integrates with Microsoft Entra ID, Google Authenticator. RSA ID Plus integrates with Active Directory, LDAP, Azure AD (Entra ID), Windows, macOS and 6 more. Check integration compatibility with your existing security stack before deciding.

BIO-key PortalGuard and RSA ID Plus serve similar MFA & Passwordless use cases: both are MFA & Passwordless tools, both cover Authentication, MFA, Single Sign On. Review the feature comparison above to determine which fits your requirements.